Clinical Trial Update: Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC [Phase 2]

View source ↗

Summary

Phase 2 study evaluating osimertinib combined with stereotactic ablative radiation (SABR) in EGFR-mutant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Status: ACTIVE_NOT_RECRUITING